Quality Committee
Meeting
July 27, 2026
10:00am - 11:00am Eastern Time
Announcements
PONV-05 Revision
OME Measure Review - Clark Fisher, MD, Yale New Haven Health
Glycemic Management Updates
MPOG Web App Updates
Agenda
Meeting Minutes
May 18, 2026
Roll Call – via Zoom or contact
MPOG
2026 Meetings
Friday, October 16, 2026
MPOG Retreat, San Diego, CA
Announcements
Anthony Edelman MD MBA
Thank you Tony and good
luck in your new role!
Associate QI Director Transitions
Welcome Allison Janda, MD!
● Assistant Professor Anesthesiology, University of
Michigan
● Chair, MPOG Cardiac Subcommittee
● CoPI - VEGA2
New Associate QI Director
2025 Consensus Guidelines
• Dr. TJ Gan presented on PONV at
2025 MPOG Retreat – for propofol
to be an effective antiemetic,
“…patient needs a dose of 90-100
mcg/kg/min…”
• MPOG is proposing a minimum dose
of 50 mcg/kg/min for ≥ 5 minutes
Propofol infusion spec
Effect of Propofol Infusion on Need for Rescue... : Anesthesia & Analgesia
Dexmedetomidine
• Issues with the studies and meta-analysis: dosing was
highly variable (one study assessed 1 mcg/kg before
incision) and almost all of the studies were quite small (
< 100 patients),
• Overall quality of evidence not great
• 5th consensus guidelines for PONV includes a
description of dexmedetomidine in the text, but it is not
included in Table 1 - list of included antiemetics (maybe
because correct dosing for PONV is unknown?)
• MPOG Coordinating Center plan: do not include in
PONV 05
OME: MME, IV, Pharmocokinetics
1 vote/ site
1. Modify: Update MME Conversion Factors to Align with NIH HEAL Standard
2. Modify: Keep IV conversion factors and rassess use of Dinges conversions at the next
revie (2029)
3. New Measure: MME based PACU Opioid Use
4. Pilot Pharmacokinetics – Based measure of Intraoperative Opioid Use
Coordinating center will review all votes after meeting to ensure no duplication
Glucose Measures
Update
Glycemic Management Measures Across MPOG
● We already have many glycemic
management measures and more are in
development (ie ambulatory).
● We need to mitigate confusion while
helping Quality Champions and ACQRs
● Align ambulatory and non-ambulatory
measures definitions where possible to
reduce overlap and redundancy
● Ensure consistent measure specification
language.
Quality Committee Reviewer Recommendations (May 2026)
Hyperglycemia Measures (GLU-09, GLU-10, GLU-11) - Patrick Henson
• Reduce Hyperglycemia Treatment (GLU-11) treatment window from 90
minutes → 60 minutes.
• Continue including all patients with hyperglycemia, not only patients with
diabetes.
• Coordinating center to evaluate harmonizing treatment timing across
glycemic management measures where appropriate.
Hypoglycemia Measures (GLU-12, GLU-13) - Elizabeth Duggan
• Separate treatment and recheck components into distinct quality metrics.
• Add 15-minute treatment requirement for severe hypoglycemia (<54 mg/dL /
3.0 mmol/L) and maintain existing treatment expectations for BG <70 mg/dL.
Proposal – Discuss with glycemic management workgroup and then QC
● Consolidate measures by retiring intraoperative only and retaining
perioperative measures. Will still provide details about which time period a
“flag” occurs
● Separate monitoring and treatment into separate measures. Allows more
detailed information on monitoring
● Update time frame for checking from 90 minutes to 60 minutes
● Update hypoglycemia measure per recent review by Dr. Duggan
GLU-17 : Hyperglycemia Treatment, Ambulatory (250 mg/dL, 13.9 mmol/L)
Percentage of adult patients undergoing an outpatient procedure with a perioperative glucose >250 mg/dL (13.9
mmol/L) treated with insulin within 60 minutes
Inclusions
● All patients undergoing an outpatient procedure (determined by Admission Type: Outpatient value code
501) with glucose level > 250 mg/dL (13.9 mmol/L)
Exclusions
● Age < 18 years
● ASA 5 & 6 including Organ Procurement (determined by Procedure Type: Organ Procurement value
code: 1)
● Any case not determined to be outpatient (determined by Admission Type value codes 0, 500, 502, 503,
504, 505, 515)
● Cases with measure duration (Preop Start to PACU End) ≤ 30 minutes
Success Criteria
Administration of insulin within 60 minutes of a blood glucose > 250 mg/dL (13.9 mmol/L).
Target Release: August 2026
Next Steps
● Maintain GLU-11 as specified through 2027 P4P/VBR measurement
period
● Publish Hyperglycemia Treatment (250 mg/dL), Ambulatory measure in
August 2026
● Glycemic Management Workgroup meeting (August 13th) to review and
refine the proposed portfolio.
● Review with Quality Committee and publish
MPOG Web App
Updates
MPOG DATA LIBRARY
Current state of MPOG web application browsers
• Three separate browsers: Concepts, Phenotypes, Measures
• Hosted on different platforms and user interface/design is not aligned
• Difficult to find related data elements
Thank you!
